Course

The Challenging Nature of Systemic Lupus Erythematosus: Treatment Issues

Upon completion of this activity, participants should be able to: (1) Assess recent evidence regarding the benefits and limitations of mainstay treatments used to treat SLE, (2) Discuss the mechanisms of action, appropriate patient populations, and safety considerations of recently approved and investigational agents used in the treatment of SLE, and (3) Identify common reasons for nonadherence in patients with SLE and develop strategies to overcome adherence barriers...

0 out of 3 steps completed0%
0 Lessons

The Challenging Nature of Systemic Lupus Erythematosus: Treatment Issues

Faculty

Monica Richey, MSN, ANP-BC/GNP
Nurse Practitioner
Northwell Health, Division of Rheumatology
New York, NY

Kayla Joseph
SLE patient

Target Audience

This activity has been designed to meet the educational needs of rheumatology nurses, nurse practitioners, and physician assistants. Other healthcare providers may also participate.

Learning Objectives and Goals:

Upon completion of this activity, participants should be able to:
1. Assess recent evidence regarding the benefits and limitations of mainstay treatments used to treat SLE
2. Discuss the mechanisms of action, appropriate patient populations, and safety considerations of recently approved and investigational agents used in the treatment of SLE
3. Identify common reasons for nonadherence in patients with SLE and develop strategies to overcome adherence barriers

Accreditation Statement

Rheumatology Nurses Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (Provider No. P0500). Rheumatology Nurses Society designates this educational activity for 0.50 CNE contact hours.

Disclosure Statement

According to the disclosure policy of RNS, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

Relationships are abbreviated as follows:

  • E, Educational planning committee
  • G, Grant/research support recipient
  • A, Advisor/review panel member
  • C, Consultant
  • S, Stock shareholder
  • SB, Speaker bureau; PE
  • Promotional event talks
  • H, Honoraria
  • O, Other

Disclosures are as follows:

Monica Richey, MSN, ANP-BC/GNP, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Celgene, Novartis/C; Mallinckrodt/SB.

Kayla Joseph has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Planning Committee

Kim Cheramie, MSN, RN-BC, Lead Nurse Planner, Rheumatology Nurses Society, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Scott Kober, MBA, President, MedCaseWriter, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Kevin Lyons, Executive Director of the Rheumatology Nurses Society and Chief Executive Officer of Lyons Den Solutions, LLC, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Off-Label Product Disclosure

This activity will not include a discussion of off-label or investigational use of products.

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE contact hours for your participation, please complete the post-test (achieving a passing grade of 75% or greater), and program evaluation. Your certificate can be printed immediately.

Supporter

This activity is supported by an educational grant from GSK